Uday Kumar S. is a Founder at VRise Therapeutics, Inc. He is an industry leader with expertise in strategic biotech operations and is familiar with a wide range of pioneering therapeutic technologies. Uday has over 20 years of academic and industry experience and a successful track record of consistently guiding products from early discovery pipelines to late-clinical stages. He has worked with some of the most successful biotech companies in the world in several therapeutic areas including oncology, inflammation, metabolic disorders, pain and inhalation technology.

Uday is actively involved in helping biotech companies position their assets and has worked alongside a variety of regulatory agencies including the USFDA, TGA, NAPHISA, HEALTH CANADA, MHRA, NMPA, AIFA, EMEA and DCGI. From 2010 to 2021, Uday served as founding member in Rhizen, a privately owned biotech company most recently as Vice President, Scientific Affairs. He played an instrumental role in the development and early commercialization of Umbralisib (Licensed to TG Therapeutics Inc and approved by USFDA under the trade name Ukoniq^TM). He has been actively involved in discussions with regulatory agencies for clinical protocols (SPAs inclusive); fast track and orphan designations; and other expedited approval pathways.

Earlier in his career, Uday also worked from 2004 to 2010 at Glenmark, and before this, at Ranbaxy and the National Chemical Laboratory. His primary expertise includes regulatory sciences, project management, R&D financing, due diligence, alliance management, manufacturing, quality and clinical operations. Uday Kumar holds a M.Pharm. (Honors) from University of Indore; a management degree from the Indian Institute of Management, Lucknow; and a PGD in intellectual property rights from ICFAI.